Finance

Lists
Why is RGNX down 4.86%?
Dive Deeper
RGNX:NASDAQ
Regenxbio Inc
$7.64
-4.86%
(-0.39) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGNX...
Open
$8.02
High
$8.04
Low
$7.39
Mkt. cap
505.18M
Avg. vol.
1.37M
Volume
716.13K
52-wk high
$16.19
52-wk low
$5.46
EPS
-$3.21
Beta
1.24
Shares outstanding
66.12M
No. of employees
371
Open
$8.02
High
$8.04
Low
$7.39
Mkt. cap
505.18M
Avg. vol.
1.37M
Volume
716.13K
52-wk high
$16.19
52-wk low
$5.46
EPS
-$3.21
Beta
1.24
Shares outstanding
66.12M
No. of employees
371
News stories
From web sources and news partners
About Regenxbio Inc
CEO-
Employees371
Founded2008
HeadquartersRockville, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websiteregenxbio.com
Analyst ratings
Based on 11 analysts giving stock ratings to RGNX in the past 3 months
Strong buy
Buy
9
Hold
2
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for RGNX in the last 3 months.
Highest
Current $7.64
$42.00 (+449.74%)
Average
$20.91 (+173.69%)
Lowest
$10.00 (+30.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Maintained
$18.00
+135.6%
11/06/2026
Luca Issi
RBC Capital
Buy
Maintained
$19.00
+148.7%
11/05/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$21.00
+174.9%
11/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$14.00
+83.2%
11/06/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$18.00
+135.6%
11/06/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$25.00
+227.2%
11/06/2026
Eliana Merle
Barclays
Hold
Maintained
$12.00
+57.1%
11/06/2026
Paul Choi
Goldman Sachs
Hold
Maintained
$10.00
+30.9%
10/20/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$42.00
+449.7%
10/21/2026
Lili (Aurélie) Nsongo
Leerink Partners
Buy
Maintained
$19.00
+148.7%
10/12/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$18.00
+135.6%
08/24/2026
Mara Goldstein
Clear Street
Buy
Maintained
$32.00
+318.8%
08/25/2026
William Maughan
Clear Street
Buy
Maintained
$32.00
+318.8%
08/24/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
$17.00
+122.5%
05/15/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$52.00
+580.6%
01/28/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$1.21 / -$1.30
+7.03%beat
Revenue / Est. (USD)
9.16M / 11.48M
-20.20%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
30.34M
6.39M
108.02M
9.16M
Cost of goods sold
65.54M
68.41M
57.13M
62.15M
Cost of revenue
65.54M
68.41M
57.13M
62.15M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.38M
21.31M
21.62M
20.58M
Operating expense
22.43M
21.34M
21.63M
20.57M
Total operating expenses
87.97M
89.76M
78.76M
82.72M
Operating income
-57.64M
-83.36M
29.26M
-73.56M
Other non operating income
-
-
-
-
EBT including unusual items
-67.15M
-90.05M
22.71M
-40.74M
EBT excluding unusual items
-67.15M
-90.05M
22.71M
-78.76M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
54.00K
36.00K
12.00K
-7.00K
Net income
-67.15M
-90.05M
22.71M
-40.74M
Net profit margin
-221.34%
-1,408.59%
21.02%
-444.64%
Earnings per share
-1.30
-1.72
0.43
-1.21
Interest and investment income
2.76M
2.02M
1.24M
2.27M
Interest expense
-12.28M
-8.71M
-7.79M
-7.47M
Net interest expenses
-9.51M
-6.69M
-6.55M
-5.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-53.77M
-79.50M
33.02M
-70.04M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps